- Page 1 and 2: Efficacy of pharmacological interve
- Page 3 and 4: 2.2.7 Clinical Course of IPF.......
- Page 5 and 6: CHAPTER I: INTRODUCTION Idiopathic
- Page 7 and 8: Progression-Free Survival (PFS) in
- Page 9 and 10: is used (Azuma et al., 2005). The p
- Page 11 and 12: Source: Adopted from Myllärniemi a
- Page 13 and 14: disease is increased; however, no s
- Page 15 and 16: CHAPTER II: LITERATURE REVIEW 2.1 I
- Page 17 and 18: The dangerous disease basically att
- Page 19 and 20: made between the inflammatory and f
- Page 21 and 22: (Giotopoulos et al., 2007). RT of t
- Page 23 and 24: derived cytokines, IL-5 and IL-9, m
- Page 25 and 26: granulomatous lung disease, hence i
- Page 27 and 28: infection and IPF (Wangoo et al., 1
- Page 29 and 30: 2.2.6 Pathophysiology Though the pa
- Page 31 and 32: smoking (Rosas et al., 2007; Steele
- Page 33 and 34: histological pattern of UIP in the
- Page 35 and 36: The aim of this procedure is to rec
- Page 37 and 38: procedures involving internal valid
- Page 39 and 40: adiological diagnosis of HRCT (Ragh
- Page 41: 2.2.11.1 Clinical Predictors Age: A
- Page 45 and 46: studies and have exhibited that inc
- Page 47 and 48: Numerous physiologic parameters lik
- Page 49 and 50: Dense fibrosis and honeycombing is
- Page 51 and 52: Pharmacological treatment: Glucocor
- Page 53 and 54: i. Oxygen Therapy and ventilation I
- Page 55 and 56: Numerous patients with IPF acquirin
- Page 57 and 58: should be undergone to reveal wheth
- Page 59 and 60: CHAPTER III: RESEARCH METHODOLOGY T
- Page 61 and 62: 3.2 Meta-analysis of Randomised Con
- Page 63 and 64: 3.4.1 Inclusion criteria The inclus
- Page 65 and 66: 3.6.1 Dichotomous Comparisons The v
- Page 67 and 68: CHAPTER IV: RESULTS 4.1 Introductio
- Page 69 and 70: Following are the questions of the
- Page 71: Study number Table 2- CASP assessme
- Page 75: primary objective is to examined wh
- Page 79: to NAC inhaled inhaled NAC and oral
- Page 82: S. no Author; Year 1 Behr et al 7 C
- Page 86: pirfenidone combined with highdose
- Page 90: or temporary cessation of pirfenido
- Page 93:
4.5 Patient characteristics, interv
- Page 97:
oom air 3 Sakamoto et al 15 Effecti
- Page 101 and 102:
Of the studies considered for the s
- Page 103:
4.6 Evaluation of Efficacy of Prife
- Page 107:
change in the lowest SPO2 during th
- Page 111:
PaO2, and SaO2; episodes of AE-IPF
- Page 115 and 116:
The efficacy of using NAC in combin
- Page 117 and 118:
group. It is revealed that at the 2
- Page 119 and 120:
CHAPTER V: DISCUSSION AND CONCLUSIO
- Page 121 and 122:
contradicting results 50 51 . A res
- Page 123 and 124:
tolerability and safety of pirfenid
- Page 125 and 126:
equired. An exploratory efficacy an
- Page 127 and 128:
as to verify the results and acquir
- Page 129 and 130:
© 2017-2018 All Rights Reserved, N
- Page 131 and 132:
American Thoracic Society. Idiopath
- Page 133 and 134:
and clinical immunology. 115 (1). p
- Page 135 and 136:
Behr, J., Maier, K., Degenkolb, B.,
- Page 137 and 138:
Bowling, A. (2009). Research Method
- Page 139 and 140:
878-81. Available from: http://www.
- Page 141 and 142:
http://www.ncbi.nlm.nih.gov/pubmed/
- Page 143 and 144:
El-Chemaly, S., Ziegler, S.G., Cala
- Page 145 and 146:
Flaherty, K.R., Andrei, A.-C., Murr
- Page 147 and 148:
pirfenidone on the generation of re
- Page 149 and 150:
Hansell, D.M., Bankier, A.A., MacMa
- Page 151 and 152:
proteoglycan deposition in the airw
- Page 153 and 154:
Nishimura, J. & Inoue, T. (2009). A
- Page 155 and 156:
313-9. Available from: http://www.n
- Page 157 and 158:
Pereira, C.A., Sahn, S.A., Sussman,
- Page 159 and 160:
interstitial pneumonia: the prognos
- Page 161 and 162:
Leslie, K.O., Gruden, J.F., Parish,
- Page 163 and 164:
America. 25 (4). pp. 709-721. Marti
- Page 165 and 166:
Meyer, A., Buhl, R. & Magnussen, H.
- Page 167 and 168:
Moseley, P.L., Hemken, C. & Hunning
- Page 169 and 170:
topics/topics/idiopathic-pulmonary-
- Page 171 and 172:
Olson, A.L., Swigris, J.J., Lezotte
- Page 173 and 174:
Piguet, P.F., Vesin, C., Grau, G.E.
- Page 175 and 176:
open-label Phase II study. American
- Page 177 and 178:
Rødningen, O.K., Børresen-Dale, A
- Page 179 and 180:
Experimental Biology and Medicine.
- Page 181 and 182:
Silva, C.I.S., Müller, N.L., Fujim
- Page 183 and 184:
Sutton, A.J. (2000). Methods for me
- Page 185 and 186:
(11). pp. 1085-1094. Tomioka, H., K
- Page 187 and 188:
Wang, Q., Zhu, H., Zhou, W.-G., Guo
- Page 189 and 190:
http://www.nature.com/doifinder/10.
- Page 191 and 192:
silica-induced lung fibrosis in the